These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29218458)

  • 1. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds.
    Habert MO; Bertin H; Labit M; Diallo M; Marie S; Martineau K; Kas A; Causse-Lemercier V; Bakardjian H; Epelbaum S; Chételat G; Houot M; Hampel H; Dubois B; Mangin JF;
    Ann Nucl Med; 2018 Feb; 32(2):75-86. PubMed ID: 29218458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
    Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
    Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
    Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
    Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
    Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
    Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
    J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
    Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
    J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
    Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
    J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of 18F-florbetapir PET: comparison of two analysis methods.
    Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD;
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study.
    Ettore E; Bakardjian H; Solé M; Levy Nogueira M; Habert MO; Gabelle A; Dubois B; Robert P; David R
    Sleep; 2019 Sep; 42(9):. PubMed ID: 31267124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.
    Navitsky M; Joshi AD; Kennedy I; Klunk WE; Rowe CC; Wong DF; Pontecorvo MJ; Mintun MA; Devous MD
    Alzheimers Dement; 2018 Dec; 14(12):1565-1571. PubMed ID: 30006100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized classification of
    Bullich S; Seibyl J; Catafau AM; Jovalekic A; Koglin N; Barthel H; Sabri O; De Santi S
    Neuroimage Clin; 2017; 15():325-332. PubMed ID: 28560157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.